Nuclear MedicineTumor ImagingOncoScint (Satumomab Pendetide):Scott WilliamsApr 2, 2002FacebookLinkedInX (Twitter)Pinterest Add us as a preferred source on Google OncoScint (Satumomab Pendetide): General: Chemistry and Pharmacology Distribution Indications for the Oncoscint exam Colorectal carcinoma: Recurrent Disease Liver Mets Extrahepatic Abdominal Mets Ovarian Carcinoma Complications/Side Effects: General HAMA Formation FacebookLinkedInX (Twitter)Pinterest Add us as a preferred source on Google Latest in Tumor ImagingTumor > Therapy > Xofigo and other Prostate AgentsAugust 16, 2017Tumor > Therapy > Xofigo and PSMA therapiesJanuary 26, 2015SponsoredWebinar: AI for CT & PET/CT ImagingJune 4, 2026Tumor > Therapy > MicrospheresJanuary 31, 2008Related StoriesNuclear MedicineProstascint (111In-Capromab Pendetide) (CYT-356)Nuclear MedicineTc-99m-Arcitumomab (CEA-Scan)Tumor ImagingThallium Tumor Imaging:Sponsor ContentWebinar: AI for CT & PET/CT Imaging